IRIS
GENOVA, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.241
AS - Asia 2.085
NA - Nord America 1.269
SA - Sud America 209
AF - Africa 45
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.856
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.855
US - Stati Uniti d'America 1.215
SG - Singapore 841
CN - Cina 593
VN - Vietnam 353
FR - Francia 147
BR - Brasile 127
HK - Hong Kong 95
FI - Finlandia 60
DE - Germania 46
AR - Argentina 36
IN - India 34
JP - Giappone 30
GB - Regno Unito 29
ID - Indonesia 22
NL - Olanda 22
BD - Bangladesh 21
CA - Canada 20
ZA - Sudafrica 17
MX - Messico 15
RU - Federazione Russa 12
TR - Turchia 11
EC - Ecuador 10
MY - Malesia 10
PY - Paraguay 10
UZ - Uzbekistan 10
CH - Svizzera 9
IQ - Iraq 9
PH - Filippine 9
CO - Colombia 8
ES - Italia 7
PL - Polonia 7
DZ - Algeria 6
RO - Romania 6
UA - Ucraina 6
VE - Venezuela 6
AU - Australia 5
IE - Irlanda 5
SA - Arabia Saudita 5
UY - Uruguay 5
JM - Giamaica 4
NP - Nepal 4
PK - Pakistan 4
RS - Serbia 4
SE - Svezia 4
EG - Egitto 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
HR - Croazia 3
KE - Kenya 3
KW - Kuwait 3
LB - Libano 3
MA - Marocco 3
OM - Oman 3
PE - Perù 3
SV - El Salvador 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AO - Angola 2
AT - Austria 2
AZ - Azerbaigian 2
BE - Belgio 2
CL - Cile 2
CR - Costa Rica 2
GA - Gabon 2
GE - Georgia 2
JO - Giordania 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NI - Nicaragua 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
AL - Albania 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RE - Reunion 1
Totale 15.851
Salva come PNG Salva come JPEG
Città #
Genoa 5.229
Genova 3.882
Vado Ligure 1.284
Rapallo 1.273
Singapore 383
San Jose 286
Ashburn 271
Council Bluffs 137
Lauterbourg 136
Ho Chi Minh City 106
Hong Kong 90
St Louis 81
Hanoi 79
Beijing 72
Helsinki 54
New York 53
Frankfurt am Main 37
Bordighera 26
Santa Clara 25
Tokyo 25
Los Angeles 24
Milan 18
Amsterdam 15
Chicago 15
Tianjin 15
Da Nang 14
São Paulo 14
Orem 13
Haiphong 12
Biên Hòa 11
Atlanta 10
City of London 10
New Delhi 10
Guangzhou 9
Jamaica Plain 9
Mexico City 9
Naples 9
Buffalo 8
Johannesburg 8
Rome 8
Hải Dương 7
Montreal 7
Rio de Janeiro 7
Tashkent 7
Dallas 6
Jakarta 6
Lappeenranta 6
Padua 6
Phủ Lý 6
Shenzhen 6
Warsaw 6
Asunción 5
Bologna 5
Can Tho 5
Chennai 5
Dublin 5
Guayaquil 5
North Charleston 5
Shanghai 5
Turin 5
Zurich 5
Baghdad 4
Buenos Aires 4
Cardiff 4
Houston 4
Istanbul 4
Kuala Lumpur 4
London 4
Madrid 4
Stockholm 4
Addis Ababa 3
Bandung 3
Brescia 3
Bình Dương 3
Bắc Giang 3
Bắc Ninh 3
Campinas 3
Denver 3
Dhaka 3
Hefei 3
Jeddah 3
Kuwait City 3
La Plata 3
Manchester 3
Monte Grande 3
Montevideo 3
Mumbai 3
Nairobi 3
Ninh Bình 3
Parma 3
Phúc Yên 3
Resistencia 3
Salt Lake City 3
Suzhou 3
Sydney 3
Toronto 3
Vinh 3
Wuhan 3
Zagreb 3
Algiers 2
Totale 14.015
Salva come PNG Salva come JPEG
Nome #
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. 276
Efficacy of motesanib diphosphate in non-small-cell lung cancer. 184
Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 176
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 175
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 172
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 172
Harnessing NK Cells for Cancer Treatment 171
Next Generation Sequencing In Non-Small Cell Lung Cancer: New Avenues Toward The Personalized Medicine. 167
Belagenpumatucel-L for the treatment of non-small cell lung cancer 167
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 165
CORRELATION BETWEEN B7-H4 EXPRESSION AND SURVIVAL OF NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH NIVOLUMAB 161
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 160
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 156
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 156
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells 151
Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 148
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 148
Radiomic detection of EGFR mutations in NSCLC 148
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 146
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 146
Oral vinorelbine in the treatment of non-small-cell lung cancer. 145
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 145
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 141
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 141
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 141
Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports 140
Afatinib for the treatment of advanced non-small-cell lung cancer. 138
Expression of ribonucleotide reductase subunit-2 and thymidylate synthase correlates with poor prognosis in patients with resected stages I-III non-small cell lung cancer 136
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 135
Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients 135
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. 135
Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM™ platform 135
Novel emerging molecular targets in non-small cell lung cancer 135
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors 133
Immune Checkpoint Inhibitors-Related Myastenia Gravis, Myocarditis and Myositis: A Systematic Review of Cases 132
Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study 132
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 132
Prognostic value of immunotherapy-induced organ inflammation assessed on 18FDG PET in patients with metastatic non-small cell lung cancer 132
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors 131
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 130
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 130
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 129
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 128
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 128
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry 127
Afatinib for the treatment of non-small cell lung cancer 126
An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update 126
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 125
An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis 122
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 122
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer 121
Approaches to Fertility Preservation for Young Women With Breast Cancer 120
Potential application of cryobiopsy for histo-molecular characterization of mediastinal lymph nodes in patients with thoracic malignancies: a case presentation series and implications for future developments 119
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 118
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 118
Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management 117
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 117
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 115
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 113
Role of microRNAs in malignant mesothelioma. 112
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 112
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics 112
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 110
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade 110
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 110
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: A systematic literature review highlighting differences from the idiopathic forms 109
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 108
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 107
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 105
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 105
Palliative treatment of life-threatening hemoptysis with silicone stent insertion in advanced lung cancer 104
Pemetrexed for the treatment of non-small cell lung cancer. 103
Antibody–drug conjugates for lung cancer in the era of personalized oncology 103
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 103
Radiomic-based diagnostics in oncology: challenges toward clinical practice 103
Metabolic parameters as biomarkers of response to immunotherapy and prognosis in non-small cell lung cancer (Nsclc): A real world experience 102
Vinflunine for the treatment of non-small cell lung cancer 101
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 100
Hematopoietic growth factors in lung cancer 100
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 98
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 96
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 96
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 95
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors 95
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 95
Primary endobronchial melanoma: a case report and clinical management indications 94
Call for ensuring cancer care continuity during COVID-19 pandemic 94
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer 94
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 94
Beyond first-line immunotherapy: Potential therapeutic strategies based on different pattern progressions: Oligo and systemic progression 94
Rapid On-Site Evaluation Performed by an Interventional Pulmonologist: A Single-Center Experience 93
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 93
Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples 92
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 91
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 91
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 90
Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient 89
A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines 89
Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer 89
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 89
Totale 12.460
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.685
article - articoli 62.425
book - libri 0
conference - conferenze 430
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 444
Totale 126.984
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021283 0 0 0 0 0 0 0 0 0 152 54 77
2021/20221.182 88 27 31 76 63 86 30 253 140 120 75 193
2022/20231.509 136 104 26 141 262 242 17 138 227 27 172 17
2023/20241.016 39 107 34 137 76 151 80 58 46 71 44 173
2024/20253.429 115 198 93 274 431 353 312 602 155 217 309 370
2025/20266.254 743 307 563 645 807 503 958 341 644 743 0 0
Totale 16.378